The Nasdaq-listed company said it will outline updates on Epi+Gen CHD, PrecisionCHD, reimbursement progress, ongoing and planned studies, and strategic growth initiatives during the 3 p.m. Central Time webcast.
verifying reliability
No specialized terms available for this topic.